These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28518222)

  • 1. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
    Silver RT; Barel AC; Lascu E; Ritchie EK; Roboz GJ; Christos PJ; Orazi A; Hassane DC; Tam W; Cross NCP
    Cancer; 2017 Jul; 123(14):2680-2687. PubMed ID: 28518222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.
    Ianotto JC; Chauveau A; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; de Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Benbrahim O; Ugo V; Lippert E; Kiladjian JJ
    Haematologica; 2018 Mar; 103(3):438-446. PubMed ID: 29217781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report.
    Silver RT; Vandris K; Goldman JJ
    Blood; 2011 Jun; 117(24):6669-72. PubMed ID: 21518929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.
    Pizzi M; Silver RT; Barel A; Orazi A
    Mod Pathol; 2015 Oct; 28(10):1315-23. PubMed ID: 26271725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.
    Abu-Zeinah G; Qin A; Gill H; Komatsu N; Mascarenhas J; Shih WJ; Zagrijtschuk O; Sato T; Shimoda K; Silver RT; Mesa R
    Ann Hematol; 2024 Sep; 103(9):3573-3583. PubMed ID: 39145781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
    O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
    Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH; Rajan R; Emadi A
    Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis].
    Xu ZF; Li B; Liu JQ; Li Y; Ai XF; Zhang PH; Qin TJ; Zhang Y; Wang JY; Xu JQ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):576-80. PubMed ID: 27535857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.
    Sørensen AL; Skov V; Kjær L; Bjørn ME; Eickhardt-Dalbøge CS; Larsen MK; Nielsen CH; Thomsen C; Rahbek Gjerdrum LM; Knudsen TA; Ellervik C; Overgaard UM; Andersen CL; Hasselbalch H
    Blood Adv; 2024 Oct; 8(20):5416-5425. PubMed ID: 39163611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.
    Ianotto JC; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; De Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Schoenwald M; Andreoli A; Abgrall JF; Kiladjian JJ
    Br J Haematol; 2013 Sep; 162(6):783-91. PubMed ID: 23848933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review.
    Zhao L; Zhang H; Chen J; Ma H; Liu B
    Hematology; 2024 Dec; 29(1):2402106. PubMed ID: 39268974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
    Sazawal S; Singh N; Mahapatra M; Saxena R
    Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
    Patel KP; Newberry KJ; Luthra R; Jabbour E; Pierce S; Cortes J; Singh R; Mehrotra M; Routbort MJ; Luthra M; Manshouri T; Santos FP; Kantarjian H; Verstovsek S
    Blood; 2015 Aug; 126(6):790-7. PubMed ID: 26124496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon.
    Hebballi S; Akiki S; Bareford D
    J Clin Pathol; 2012 Aug; 65(8):762-3. PubMed ID: 22412053
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
    Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
    Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational profiling in myelofibrosis: implications for management.
    Bose P; Verstovsek S
    Int J Hematol; 2020 Feb; 111(2):192-199. PubMed ID: 31630335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.